<?xml version='1.0' encoding='utf-8'?>
<document id="6313143"><sentence text="Chlorpromazine and lithium interaction: a biochemical and histological study."><entity charOffset="0-14" id="DDI-PubMed.6313143.s1.e0" text="Chlorpromazine" /><entity charOffset="19-26" id="DDI-PubMed.6313143.s1.e1" text="lithium" /><pair ddi="false" e1="DDI-PubMed.6313143.s1.e0" e2="DDI-PubMed.6313143.s1.e0" /><pair ddi="false" e1="DDI-PubMed.6313143.s1.e0" e2="DDI-PubMed.6313143.s1.e1" /></sentence><sentence text="Biochemical and histological studies on the effect of separate and combined administration of LiCl and of chlorpromazine (CPZ) on female C57BL/6J mice were performed"><entity charOffset="106-120" id="DDI-PubMed.6313143.s2.e0" text="chlorpromazine" /><entity charOffset="122-125" id="DDI-PubMed.6313143.s2.e1" text="CPZ" /><pair ddi="false" e1="DDI-PubMed.6313143.s2.e0" e2="DDI-PubMed.6313143.s2.e0" /><pair ddi="false" e1="DDI-PubMed.6313143.s2.e0" e2="DDI-PubMed.6313143.s2.e1" /></sentence><sentence text=" Mice were divided into 4 groups" /><sentence text=" One group was given an intraperitoneal injection daily of CPZ HCl, 5 mg/kg for 4 days followed by 4 more days of a daily dosage of 10 mg/kg"><entity charOffset="59-66" id="DDI-PubMed.6313143.s4.e0" text="CPZ HCl" /></sentence><sentence text=" A second group was maintained on 0" /><sentence text="4% (w/v) LiCl solution as the sole drinking fluid for 8 consecutive days and a third group received the same LiCl solution but with daily CPZ injection as the initial group for 8 days"><entity charOffset="9-13" id="DDI-PubMed.6313143.s6.e0" text="LiCl" /><entity charOffset="138-141" id="DDI-PubMed.6313143.s6.e1" text="CPZ" /><entity charOffset="109-112" id="DDI-PubMed.6313143.s6.e2" text="LiCl" /><pair ddi="false" e1="DDI-PubMed.6313143.s6.e0" e2="DDI-PubMed.6313143.s6.e0" /><pair ddi="false" e1="DDI-PubMed.6313143.s6.e0" e2="DDI-PubMed.6313143.s6.e2" /><pair ddi="false" e1="DDI-PubMed.6313143.s6.e0" e2="DDI-PubMed.6313143.s6.e1" /><pair ddi="false" e1="DDI-PubMed.6313143.s6.e2" e2="DDI-PubMed.6313143.s6.e2" /><pair ddi="false" e1="DDI-PubMed.6313143.s6.e2" e2="DDI-PubMed.6313143.s6.e1" /></sentence><sentence text=" The fourth group served as saline-controls" /><sentence text=" Hepatic liver alcohol dehydrogenase was induced by combined drug treatment from respective controls"><entity charOffset="15-22" id="DDI-PubMed.6313143.s8.e0" text="alcohol" /></sentence><sentence text=" The Li-treatment inhibited mitochondrial liver aldehyde dehydrogenase, and coadministration of CPZ with LiCl antagonized this effect"><entity charOffset="48-56" id="DDI-PubMed.6313143.s9.e0" text="aldehyde" /><entity charOffset="96-103" id="DDI-PubMed.6313143.s9.e1" text="CPZ" /><entity charOffset="105-112" id="DDI-PubMed.6313143.s9.e2" text="LiCl" /><pair ddi="false" e1="DDI-PubMed.6313143.s9.e0" e2="DDI-PubMed.6313143.s9.e0" /><pair ddi="false" e1="DDI-PubMed.6313143.s9.e0" e2="DDI-PubMed.6313143.s9.e1" /><pair ddi="false" e1="DDI-PubMed.6313143.s9.e0" e2="DDI-PubMed.6313143.s9.e2" /><pair ddi="false" e1="DDI-PubMed.6313143.s9.e1" e2="DDI-PubMed.6313143.s9.e1" /><pair ddi="false" e1="DDI-PubMed.6313143.s9.e1" e2="DDI-PubMed.6313143.s9.e2" /></sentence><sentence text=" Mice treated with CPZ showed corneal cellularity and mitotic figure appearance without inflammation"><entity charOffset="19-22" id="DDI-PubMed.6313143.s10.e0" text="CPZ" /></sentence><sentence text=" The LiCl treated mice displayed variations in base corneal cell size, shape and pigmentation with aggregation of the nuclei, and the presence of mitotic activity inflammation"><entity charOffset="5-7" id="DDI-PubMed.6313143.s11.e0" text="LiCl" /></sentence><sentence text=" Mice receiving combined drug treatment showed similar corneal alterations, but mitotic figures were found above base cell layer suggesting an enhanced corneal toxicity" /><sentence text=" The results suggest a drug-drug interaction phenomenon which may explain some of their adverse reaction when given concurrently" /><sentence text="" /></document>